IRD: Opus Genetics cites positive Cohort 1 low-dose Phase 1/2 data
Opus Genetics reported positive low-dose Cohort 1 data from Phase 1/2 trial of OPGx-BEST1 and a successful FDA Type C meeting.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.